A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three m...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1998, Vol.16 (4), p.337-340
Main Authors: BERG, W. J, MCCAFFREY, J, SCHWARTZ, L. H, MARIANI, T, MAZUMDAR, M, MOTZER, R. J
Format: Article
Language:English
Subjects:
Acridines - therapeutic use
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Blood tests
Cancer therapies
Carcinoma, Renal Cell - drug therapy
Chemotherapy
Cytokines
Cytotoxicity
Female
Humans
Immunotherapy
Kidney cancer
Kidney Neoplasms - drug therapy
Life expectancy
Male
Medical sciences
Metastasis
Middle Aged
Neutropenia
Patients
Pharmacology. Drug treatments
Pyrazoles - therapeutic use
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.
ISSN:0167-6997
1573-0646
DOI:10.1023/A:1006143008040